Results 101 to 110 of about 455,754 (315)
Loss of Stat3 in Prx1+ Progenitors Impairs Molar Root Development
Stat3 critically regulates mandibular first molar and alveolar bone morphogenesis. Conditional ablation of Stat3 disrupts the osteogenic capacity of Prx1+ mesenchymal progenitors, as evidenced across in vivo and in vitro models. Abstract Signal Transducer and Activator of Transcription 3 (Stat3) acts as a central transcriptional modulator coordinating ...
Xin Feng +10 more
wiley +1 more source
Background: Chronic myeloid leukaemia is a clonal myeloproliferative disorder of myeloid progenitor cells. The availability of moleculartargeted therapy with tyrosine kinase inhibitors has changed the course and treatment for patients with chronic ...
Frosina Krstanovska +4 more
doaj
Establishment of in vitro Src tyrosine kinase inhibitors screening model
A model system for rapid screening of Src tyrosine kinase inhibitors was established in vitro, and it is the foundation of screening tyrosine kinase activity inhibitors.
WANG Chen-hui, SHI Ying, GONG Xing-guo
doaj +1 more source
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients [PDF]
open25noSecond-generation tyrosine kinase inhibitors (2G-TKIs) dasatinib and nilotinib produced historical rates of about 50% complete cytogenetic response (CCyR) and about 40% major molecular response (MMR) in chronic myeloid leukaemia (CML) patients ...
core +1 more source
The review provides a critical up‐to‐date overview of the current landscape of human in vitro models for fatty liver disease, including spheroids, organoids, organ‐on‐a‐chip systems, bioprinted liver constructs and precision‐cut liver slices. Their utility for faithfully modeling different stages of MASLD and MASH are evaluated and their compatibility ...
Sonia Youhanna +6 more
wiley +1 more source
Knockdown of annexin A5 restores gefitinib sensitivity by promoting G2/M cell cycle arrest
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, including gefitinib, are first-line drugs against advanced non-small cell lung cancer with activating EGFR mutations. However, the development of resistance to such drugs is a
Jian Zhou +5 more
doaj +1 more source
Cluster analysis of deterioration sites after first-line epidermal growth factor receptor-tyrosine kinase inhibitor in epidermal growth factor receptor mutated non-small cell lung cancer [PDF]
Shinichiro Okauchi +2 more
openalex +1 more source
A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells [PDF]
Nuclear erythroid related factor-2 (NRF2) is known to promote cancer therapeutic detoxification and crosstalk with growth promoting pathways. HER2 receptor tyrosine kinase is frequently overexpressed in cancers leading to uncontrolled receptor activation
Bown, James +6 more
core +3 more sources
A biofabricated 3D in vitro model recapitulating endochondral ossification (ECO) is described, mimicking the steps from condensation to chondrogenesis and hypertrophy, culminating with vascularization of the hypertrophic construct. As a model proof of concept application, Ewing Sarcoma cells are seeded in the model, showing modifications in their ...
Maria Vittoria Colombo +13 more
wiley +1 more source
Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
The development of point mutations in the BCR-ABL kinase domain is the main reason for imatinib resistance in chronic myeloid leukemia. Different detection methods are used in chronic myeloid leukemia monitoring, such as direct sequencing, denaturing ...
Roberta Bitencourt +2 more
doaj +1 more source

